

IDS  
f.led  
2/11/05

DT01 Rec'd PCT/PTC 11 FEB 2005  
Sheet 1 of 1 (2/11/05)

Form PTO-1449	ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO. 10/524520
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)	APPLICANT LOIBNER, Hans et al.	
	FILING DATE February 11, 2005	GROUP

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
/BD/	WO	0069460	A	2000-11-23	WIPO				

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

<del>Nakashio et al. "Peritoneal Dissemination is Inhibited by Treatment With Antibodies Against CD44H, Betal, Integrin, and Carcinostatic ..." International Journal of Oncology, Vol. 10, No. 2, 1997, pp. 355-362</del>
<del>Schneider-Gaedicke et al. "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours" European Journal of Cancer, Vol. 31A, No 7-8, 1995, pp. 1326-1330</del>
<del>Reithmueller et al., "Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial" Journal of Clinical Oncology, Vol. 16, No. 5, May 1998, pp. 1788-1794</del>

EXAMINER /Brad Duffy/	DATE CONSIDERED 7/23/2007
--------------------------	------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS  
filed  
8/22/05

Form PTO-1449	ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO. 10/524,520
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)	APPLICANT LOIBNER, Hans et al.	
	FILING DATE February 11, 2005	GROUP

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/BD/	US 2001/0006618	A1	2001-07-05	Goldenberg			
/BD/	US 4,643,971		1987-02-17	Frader et al.			
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
/BD/	WO	01/23005	A1	2001-04-05	WIPO				
	<del>WO</del>	<del>00/69460</del>	<del>A1</del>	<del>2000-11-23</del>	<del>WIPO</del>				
	WO	01/03738	A1	2001-01-18	WIPO				
	WO	93/21940	A1	1993-11-11	WIPO				
	EP	1140168	B1	2002-06-26	EPO				

<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)	
<del>(Abstract) Swayne L.C. et al. " SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases" Journal Article, Vol. 16, No. 11, November 1991, pp.849-852</del>	
<del>(Abstract) Edington M.D. " Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium -111 labeled monoclonal antibody to CEA" Journal Article, Vol. 104, No. 6, December 1998, pp. 1004-1010</del>	
<del>(Abstract) Cote R.J. et al. " Intraoperative monoclonal antibody CC49" Journal Article, Vol. 77, No. 4, February 15, 1996, pp.613-620</del>	
<del>(Abstract) Lechner P. et al. " Tc-99m-labeled anti-CEA antibodies in intraoperative diagnosis of colorectal cancer" Journal Article, Vol. 34, No. 1, February 1995, pp.8-14</del>	
EXAMINER /Brad Duffy/	DATE CONSIDERED 7/23/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449		ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO.
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		APPLICANT LOIBNER, Hans et al.	
		FILING DATE February 11, 2005	GROUP
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	J.P. Chippaux and M. Goyffon. "Venoms, Antivenoms and Immunotherapy" Journal Toxicon, Vol.36, No. 6, May 7, 1997, pp. 823-846		
	G. Riethmüller. et.al. "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial" Journal of Clinical Oncology, Vol.16, No.5, May 1998, pp.1788-1794		
	Tatsuaki, Nakashima et al. " Peritoneal dissemination is inhibited by treatment with antibodies against CD44H, B1 integrin, carcinostatic agents in NUGC-4 human gastric cancer cells" International Journal of Oncology, Vol. 10, 1997, pp.355-362		
	Barchi, Joseph J. Jr. " Emerging Roles of Carbohydrates and Glycomimetics in Anticancer Drug Design" Current Pharmaceutical Design, Vol. 6, 2000, pp.485-501		
	Ben-Yedidia Tamar and Arnon Ruth. " Design of Peptide and Polypeptide vaccines" Biotechnology, Vol.8, 1997, pp.442-448		
	Casadevall, Arturo and Scharff, Matthew D. " Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases" Clinical Infectious Diseases, Vol.21, 1995, pp.150-161		
	Glennie, Martin J. and Johnson, Peter W.M. " Clinical trials of antibody therapy" Journal Immunology Today, Vol.21, no. 8, August 2000, pp.403-410		
	Gollogly, V. Castronovo. " A possible role for the alpha 1-3 galactosyl epitope and natural anti-gal antibody in ontogenesis" Neoplasma Journal, Vol.43, No.5, 1996, pp.285- 289		
	Herlyn, Dorothy and Birebent Brigitte. " Advances in cancer vaccine development" the Finnish Medical Society Duodecim, Vol.31, 1999, pp.66-78		
	Lewis, Jonathan J. and Houghton, Alan N. " Definition of tumor antigens suitable for vaccine construction" Cancer Biology, Vol.6, 1995, pp.321-327		
	Melief, Cornelis J.M. et al. " Peptide-based cancer vaccines" Current Opinion in Immunology, Vol.8, 1996, pp.651-657		
	Miyake, Masayuki. et. al. " Correlation of Expression of H/Ley/Leb Antigens with Survival in Patients with Carcinoma of the Lung" The New England Journal of Medicine, July 2, 1992, pp.14-18		
	Orntoft, F. Torber and Vestergaard, Else Marie. " Clinical aspects of altered glycosylation of glycoproteins in cancer" Electrophoresis Journal, Vol.20, 1999, pp.362-371		
	Scott, Andrew M. and Welt, Sydney. "Antibody-based immunological therapies" Journal of Current Opinion on Immunology, Vol. 9. 1997, pp.717-722		
	Weitz, Jurgen MD and Herfarath, Christian MD. " Surgical Strategies and Minimal Residual Disease Detection" Seminars in Surgical Oncology, Vol.20, 2001, pp.329-333.		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			